Hippocampal abnormalities are believed to increase the risk of cognitive decline in diabetic patients. The underlying mechanism is unknown, but both hyperglycemia and oxidative stress have been implicated. Cellular stresses induce expression of heat shock protein 25 (HSP25) and this results in cytoprotection. Our aim was to assess hippocampal expression of HSP25 in experimental diabetes. Mice were rendered diabetic by streptozotocin injection. Ten weeks after diabetes onset hippocampal HSP25 expression was studied by immunoblotting and immunohistochemistry (IHC).
Introduction
Multiple organ systems are adversely affected by diabetes, including the brain, which undergoes changes that may increase the risk of cognitive decline (Ryan et al., 1993; Ott et al., 1999; Rstow, 2004) . Studies in experimental diabetes have demonstrated progressive astrogliosis, pyramidal neuron apoptosis, altered synaptic plasticity, and reduced dendritic complexity within the hippocampus (Magariños and McEwen, 2000; Saravia et al., 2002; Valastro et al., 2002) . The underlying mechanisms of these abnormalities are unknown; however, both hyperglycemia and oxidative stress have been implicated Nishikawa et al., 2000) .
Heat Shock Proteins (HSPs) are ubiquitous, highly evolutionary conserved intracellular proteins (Ellis and van der Vies, 1991) . Thermal, oxidative, hemodynamic, osmotic, and hypoxic stresses induce HSPs expression, and this stress response results in cytoprotection (Ellis and van der Vies, 1991; Feder and Hofmann, 1999) . Specifically, HSPs prevent nonspecific protein assembly, assist in denatured protein refolding, and interfere with proapoptotic pathways (Yenari et al., 2005) .
Studies on the expression of HSPs in the diabetic hippocampus have shown that HSP60, a mitochondrial-specific molecular chaperon, is overexpressed in the hippocampal CA1 region and that HSP60 expression strongly correlates with that of superoxide dismutase (SOD) (Yuan et al., 2006) , a marker of mitochondrial oxidative stress. By contrast, no abnormalities in HSP70 expression were observed (Guven et al., 2009) . levels in hippocampal sample homogenates were expressed as nanomoles of MDA per milligram of protein.
Immunofluorescence
Expression of Cu/Zn SOD was assessed by indirect immunofluorescence using a sheep anti-mouse primary antibody (Calbiochem-Merck, Milan, Italy) and a FITC-conjugated donkey anti-sheep secondary antibody (Dako). Sections were examined using an Olympus epifluorescence microscope (Olympus Bx4I) and digitised with a high resolution camera (Carl Zeiss).
Double immunofluorescence
Double immunofluorescence was performed for HSP25 and either Cu/Zn-SOD or GFAP on hippocampal sections. After blocking, sections were incubated with either an anti-Cu/Zn-SOD antibody or an anti-GFAP antibody for 1 hour, followed by a labelled secondary antibody (Cu/Zn-SOD: FITC-conjugated donkey-anti sheep antibody; GFAP: TRITC-conjugated goat anti-mouse antibody). After washing, sections were incubated with an anti-HSP25 antibody for 18 h at 4°C, followed by 1 h incubation with a biotinylated swine anti-rabbit IgG (Dako) and then with FITC/Alexa 555-conjugated streptavidin (Invitrogen, Milan, Italy). Sections were examined using an Olympus epifluorescence microscope (Olympus Bx4 I) with photographic attachment (Carl Zeiss). The images were colour-combined and assembled into photomontages by using Adobe Photoshop (Universal Imaging, West Chester, PA).
Protein Extraction
For total protein extraction isolated hippocampal tissue was homogenised in a modified RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 µg/mL leupeptin, 1 µg/ml aprotinin, 1 mM PMSF). Lysates were then centrifuged at 10,000 g for 40 min at 4° and protein concentration measured by DC protein (BioRad Laboratories, Hercules, CA, USA). Cytosolic and nuclear extracts were prepared as previously described (Collino et al, 2006 Collino et al, 2009 . Briefly, tissues were homogenized at 10% (wt/vol) in a Potter Elvehjem homogenizer (Wheaton, Millville, NJ) using a homogenization buffer containing 20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.5 mM EDTA, 1% Nonidet P-40, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, and 2.5 μg/ml leupeptin. Homogenates were centrifuged at 1000 × g for 5 min at 4 C. Supernatants were removed and centrifuged at 105,000 × g at 4 C for 40 min to obtain the cytosolic fraction. The pelleted nuclei were resuspended in extraction buffer containing 20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 300 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, and 2.5 μg/ml leupeptin and incubated on ice for 30 min for high-salt extraction, followed by centrifugation at 15,000 × g for 20 min at 4 C. The resulting supernatants containing nuclear proteins were carefully removed and stored at −80 C.
Immunoblotting
Equal amounts of total protein were separated on a 10% SDS-polyacrylamide gel, then transferred to nitrocellulose membrane (Amersham Biosciences, Braunschweig, Germany). Following blocking of non-specific sites with 5% non-fat milk, membranes were probed with anti-HSP25, anti-HSP72 Immunoreactive bands were detected bySuperSignal West Femto chemiluminescence (Pierce, Rockford, IL, USA), visualised on a Gel-Doc system (Bio-Rad), and quantified by image J software. Tubulin (Santa Cruz Biotechnology) was used as internal control. In addition, USF-2 and β-tubulin serve as markers of nuclear and cytosolic fractions, respectively.
Statistical Analysis
The results are expressed as means ± SD. Comparisons were performed by unpaired two-tailed Student's t-test. P<0.05 was considered statistically significant.
Results

Metabolic and physiological parameters
As shown in Table 1 , after 10 weeks of diabetes both blood glucose and glycated haemoglobin levels were significantly higher in diabetic (DM) than in non-diabetic (ND) mice. Furthermore, compared to sham-injected control animals, diabetic mice showed a significant decrease in body weight.
Hippocampal astrogliosis
GFAP protein expression was studied in the hippocampus from both control and diabetic mice by western blotting. Immunoblots showed a band migrating at ~50 kDa, corresponding to the reported molecular weight of GFAP and densitometric analysis demonstrated that GFAP protein expression was significantly increased in the diabetic mice ( Figure 1I Semiquantitative analysis performed in the CA1 area showed that diabetic mice had a significant 2.5 fold increase of the GFAP-positive cellular area ( Figure 1F ) and a significant 3-fold increase in the number of GFAP positive cells (ND: 23 ± 1,05 vs DM 61 ± 0.79; p< 0.001).
Hippocampal HSP25 expression in experimental diabetes
To establish whether HSP25 expression is modulated by diabetes, we studied HSP25 protein expression in total hippocampus from both diabetic and control mice by western blotting. Total HSP25 protein expression was greater in diabetic mice and in densitometric analysis we found a significant 2.8-fold increase of HSP25 expression in diabetic animals as compared to controls (Figure 2A ). On the contrary, hippocampal HSP72 and HSP90 expression was similar in diabetic and control animals ( Figure 2B ,C).
Distribution of HSP25 staining in the diabetic hippocampus
To assess HSP25 distribution within the hippocampus, we studied HSP25 expression in hippocampal sections by immunohistochemistry. Staining for HSP25 was enhanced in diabetic mice and localised predominantly to the CA1 pyramidal neurons layer (Figure 2 D,E and GH).
Antibody specificity was confirmed by disappearance of the signal when the antibody was replaced with a non-immune isotype control antibody (Figure 2 F,I ). Double immunofluorescence for both HSP25 ( Figure 2J ) and GFAP ( Figure 2K ) confirmed the presence of a predominant HSP25 staining in the pyramidal neurons layer ( Figure 2L ), but revealed that some GFAP-positive activated astrocytes ( Figure 2K ) also stained positively for HSP25 ( Figure 2L ). At high magnification, HSP25 and GFAP exhibited differences in their spatial distribution within astrocytes. GFAP localised mainly in the cellular processes, while HSP25 was observed predominantly in the somata ( Figure 2L insert).
Markers of oxidative stress are enhanced in the diabetic hippocampus
As oxidative stress is a known inducer of HSP25, an array of oxidative stress markers was also studied in the hippocampus from control and diabetic mice. As shown in Figure 3 , in the diabetic hippocampus, there was a significant increase in nitrotyrosine staining, as assessed by both immunohistochemistry ( Figure 3A ,B) and immunoblotting ( Figure 3C ), that was paralleled by iNOS overexpression ( Figure 3D ). Hippocampal content of MDA, a marker of lipid peroxidation, was significantly higher in diabetic animals than in controls (Figure 3 E) . Finally, in diabetic mice we also observed an enhanced immunofluorescent staining for Cu/Zn SOD ( Figure 3F ,G) and a significant increased in hippocampal SOD enzymatic activity ( Figure 3H ). Double-labelling immunofluorescence showed that within the pyramidal neurons layer the positive staining for Cu/Zn SOD ( Figure 3J ) and HSP25 ( Figure 3I ) appears to localize to the same cell. However, overlapping was very modest as Hsp25 showed a more nuclear localization, whereas Cu/Zn SOD was predominantly localised in the perinuclear area ( Figure 3K ).
Intracellular distribution of HSP25 in the diabetic hippocampus
To investigate the intracellular distribution of HSP25, western blotting analysis was performed separately for nuclear and cytosolic hippocampal protein extracts. USF2, a nuclear marker, and α-tubulin, a cytosolic marker, were used to confirm nuclear and cytosolic fraction purity ( Figure 4A ).
As shown in Figure 4B , in diabetic mice HSP25 expression increased significantly in both the cytosolic and the nuclear fractions. However, HSP25 upregulation was greater in protein extracts from the nuclei, suggesting that HSP25 overexpression was paralleled by nuclear translocation ( Figure 4B ).
Discussion
In this study we have provided evidence that in experimental diabetes HSP25 is overexpressed in the hippocampus, predominantly in CA1 pyramidal neuron layer, in parallel with enhanced oxidative stress and astrogliosis. In hippocampal protein extracts HSP25 expression was greater in diabetic than in control mice as assessed by immunoblotting. On the contrary, no difference were observed in HSP72 and HSP90, suggesting that diabetes has a specific effect on HSP25. Previous studies have shown that hippocampal HSP25 is overexpressed in response to hyperthermia, preconditioning, ischemia, epileptic seizure (Benn et al., 2002; Franklin et al., 2005; Kirbach and Golenhofen, 2011) , but this is the first evidence of HSP25 overexpression in the hippocampus in experimental diabetes. In diabetic mice, HSP25 was predominantly expressed by the pyramidal neurons of the CA1 region, as assessed by immunohistochemistry. This is not surprising as the CA1 region is highly sensitive to oxidative damage due to high anion superoxide production by CA1 pyramidal neurons (Wang et al., 2005) . A HSP25 immunoreactivity of CA1 pyramidal neurons has been previously reported in vivo (Kato et al., 1999) . Furthermore, a recent study has shown that cultured hippocampal neurons overexpress HSP25 in response to heat stress, suggesting a direct cytoprotective role of HSP25 in this cell type (Kirbach and Golenhofen, 2011) . Consistent with a previous report (Saravia et al., 2002) , we found that expression of GFAP, a reliable marker of reactive astrocytes, was enhanced in the hippocampus from diabetic mice, confirming the presence of astrogliosis in experimental diabetes. The difference in GFAP staining between diabetic and control mice was particularly marked in the stratum lacunosum1 moleculare. HSP25, however, was only sporadically expressed by activated astrocytes. At variance, in experimental models of ischemia, epilepsy, and hyperthermia, HSP25 expression is restricted to reactive astrocytes (Benn et al., 2002; Franklin et al., 2005; Kirbach and Golenhofen, 2011) . The underlying mechanism of this discrepancy is unclear; however, it is possible that the predominant HSP overexpression in CA1 pyramidal neurons is a specific feature of diabetes-induced damage. In line with this hypothesis, hippocampal HSP60 is induced in CA1 pyramidal neurons in STZinduced diabetic animals (Yuan et al., 2006) , while is overexpressed by astrocytes after transient ischemia (Hwang et al., 2007) .
In diabetic mice hippocampal HSP25 overexpression occurred not only in the cytosol, but also in the nuclei. This finding is of functional relevance as in cultured hippocampal cells HSP25 nuclear translocation is important for HSP25 protective effect against DNA fragmentation and in conferring resistance to cellular stresses (Geum et al., 2002) . Furthermore, in cultured neurons, nuclear HSP25 potentiates SP1-dependent neurotrophic gene transcription, suggesting that HSP25 may exert a cytoprotective effect also through modulation of transcriptional activity (Friedman et al., 2009 ).
The underlying mechanism of HSP25 overexpression is unknown. However, oxidative stress is a likely candidate as it is a potent inducer of HSP expression (Calabrese et al., 2003; Mehlen et al., 1993) and is enhanced in the diabetic hippocampus Mastrocola et al., 2005) .
Alternatively, proteasomal stress can also be implicated as a diabetes-induced insufficiency of the proteasome system may triggers a stress response through heat shock factor 1 activation, resulting in HSP25 induction (Dantuma et al, 2010) . However, lack of HSP72/HSP90 overexpression in our model makes less likely this possibility.
To further explore the role of oxidative stress in diabetes-induced HSP25 hippocampal expression, we have also studied an array of oxidative stress markers. Cu/Zn SOD, which catalyzes the conversion of superoxide radicals to hydrogen peroxide, represents an important defence against superoxide production and an indirect index of oxidative stress. Consistent with previous results in STZ-induced diabetic rats (Huang et al., 1999) , we found an increase in Cu/Zn SOD both expression and activity in the diabetic hippocampus. In addition, we found that SOD was predominantly expressed in the CA1 pyramidal neuron layer and that SOD and HSP25 localize to the same cell, though with a diverse intracellular distribution. A recent report has demonstrated that, in the context of global cerebral ischemia, hyperglycemia can exacerbate superoxide production in hippocampal CA1 neurons, suggesting hyperglycemia as a possible mechanism of SOD induction (Muranyi and Li, 2005) .
The presence of nitrotyrosine on proteins is a marker of in vivo peroxynitrite formation from nitric oxide and superoxide. An increased nitrotyrosine expression in CA1 pyramidal neurons has been previously demonstrated in foetuses exposed to hyperglycemia because of maternal diabetes (Hockett et al., 2004) , but our work provides the first evidence of enhanced hippocampal nitrotyrosine in an adult model of experimental diabetes and identifies the CA1 pyramidal neuron layer as a specific site of enhanced peroxynitrite formation. Of interest a recent study has shown a strong nitrotyrosine immunoreactivity of CA1 pyramidal neurons in mice expressing a mutated form of SOD (Cha et al., 2000) , providing evidence of a causal link between oxidative stress and nitrotyrosine expression in this region. On the other hand, in our study we also found that iNOs protein expression was greater in diabetic than in control mice. Therefore, increased levels of nitrotyrosine containing proteins may, at least in part, reflect an increased NO production likely secondary to diabetes-induced endothelial dysfunction (Nagareddy et al., 2005) .
Reactive oxygen species degrade polyunsaturated lipids, forming MDA. This reactive aldehyde, which can cause cellular toxic stress, is thus used as a marker of oxidative stress and lipid peroxidation. In our study, hippocampal content of MDA was found significantly enhanced in diabetic mice as compared to controls. This finding is in agreement with previous studies (Grillo et al., 2003; Cosar et al., 2008) . Furthermore, it provides a more convincing and direct evidence of the presence of enhanced oxidative stress in our experimental model. HSP25 decreases reactive oxygen species and enhances levels of glutathione, the most important intracellular antioxidant (Mehlen et al., 1997; Preville et al., 1999) . Furthermore, therapeutic strategies, leading to HSP25 upregulation, diminish hippocampal neuron apoptosis in rodents (Akbar et al., 2003; An et al., 2009; Jin et al., 2006) . Therefore, the upregulation of HSP25, herein reported, may represent a protective mechanism against diabetesinduced oxidative stress and neuronal death. However, no causal relationship can be drawn from morphological studies and further investigations are required to establish whether HSP25 is solely an indicator of oxidative stress or plays a role in neuroprotection of the diabetic hippocampus. 
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